Biotech Archives - Page 142 of 795

3 minute read

Investigator-Initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat In Combination With Azacitidine To Treat Hematologic Cancers Resumes Patient Enrollment

January 3, 9:44 AM

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as

SLRX

3 minute read

American Medical Association Grants Cardio Diagnostics A Dedicated CPT PLA Reimbursement Code For Epi+Gen CHD, An AI-Powered Test For Assessing The Probability Of A Heart Attack Or Coronary Heart Disease Event

By Benzinga Newsdesk

January 3, 9:32 AM

This is the second CPT PLA code the American Medical Association (AMA) granted for the Company's AI-powered coronary heart disease tests. This significant milestone enables the acceleration of reimbursement for the

CDIO

3 minute read

Intensity Therapeutics Announced A Business Update Reflecting Progress In Its Phase 3 Sarcoma Clinical Program; FDA Provided “Study May Proceed Letter” For Phase 3 Within 30 Day Period Following IND Submission

By Benzinga Newsdesk

January 3, 9:08 AM

IND Submission for Phase 3In the fourth quarter of 2023, the Company submitted a new Investigational New Drug ("IND") to the Food and Drug Administration ("FDA"). The submission included the phase 3 protocol for a

INTS

2 minute read

Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?

By Vandana Singh

January 3, 9:07 AM

Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD)

DYN

1 minute read

Scribe Therapeutics Announced That Sanofi Has Exercised Its Option For A Second Target As Part Of The Companies’ Research Collaboration To Develop In Vivo CRISPR-based Therapeutics

By Benzinga Newsdesk

January 3, 8:10 AM

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to

SNY

2 minute read

Johnson & Johnson Shareholders’ Class Action Lawsuit Gets Nod from Federal Judge

By Vandana Singh

January 2, 3:01 PM

A federal judge's ruling in Trenton, New Jersey, has paved the way for Johnson & Johnson (NYSE: JNJ) shareholders to collectively proceed with a lawsuit alleging the company concealed information about asbestos

JNJ

1 minute read

There’s Optimism Around Longboard Pharmaceuticals’ Anti-Seizure Candidate: Analyst Boosts Price Target

By Vandana Singh

January 2, 2:55 PM

Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental

LBPH

2 minute read

GlucoTrack Announces Early Accuracy Data For Its Implantable Continuous Glucose Monitor; Announces The Successful Completion Of Their First Preclinical Study Of The Implantable CBGM

By Benzinga Newsdesk

January 2, 1:34 PM

GlucoTrack, Inc. (NASDAQ:GCTK) ("GlucoTrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides, updates on

GCTK

1 minute read

Why Is Rare Disease Focused Soligenix Stock Soaring Today?

By Vandana Singh

January 2, 11:05 AM

Soligenix Inc (NASDAQ: SNGX) announced a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against Sudan ebolavirus (SUDV) and

SNGX

1 minute read

Neurology-Focused Longboard Pharmaceuticals’ Stock Soars Over 200% Today – Here’s Why

By Vandana Singh

January 2, 10:56 AM

Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental

LBPH